Skip to main content
Top
Published in: Acta Diabetologica 5/2014

01-10-2014 | Original Article

Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients

Authors: Gianpaolo Balzano, Erica Dugnani, Valentina Pasquale, Giovanni Capretti, Maria Grazia Radaelli, Tania Garito, Gregorio Stratta, Alessandro Nini, Raffaele Di Fenza, Renato Castoldi, Carlo Staudacher, Michele Reni, Marina Scavini, Claudio Doglioni, Lorenzo Piemonti

Published in: Acta Diabetologica | Issue 5/2014

Login to get access

Abstract

To characterize the clinical signature and etiopathogenetic factors of diabetes associated with pancreas disease [type 3 diabetes mellitus (T3cDM)]. To estimate incidence and identify predictors of both diabetes onset and remission after pancreatic surgery. A prospective observational study was conducted. From January 2008 to December 2012, patients (n = 651) with new diagnosis of pancreatic disease admitted to the Pancreatic Surgery Unit of the San Raffaele Scientific Institute were evaluated. Hospital and/or outpatient medical records were reviewed. Blood biochemical values including fasting blood glucose, insulin and/or C-peptide, glycosylated hemoglobin and anti-islet antibodies were determined. Diabetes onset was assessed after surgery and during follow-up. At baseline, the prevalence of diabetes was 38 % (age of onset 64 ± 11 years). In most cases, diabetes occurred within 48 months from pancreatic disease diagnosis. Among different pancreatic diseases, minor differences were observed in diabetes characteristics, with the exception of the prevalence. Diabetes appeared associated with classical risk factors for type 2 diabetes (i.e., age, sex, family history of diabetes and body mass index), and both beta-cell dysfunction and insulin resistance appeared relevant determinants. The prevalence of adult-onset autoimmune diabetes was as previously reported within type 2 diabetes. Within a few days after surgery, either diabetes remission or new-onset diabetes was observed. In patients with pancreatic cancer, no difference in diabetes remission was observed after palliative or resective surgery. Classical risk factors for type 2 diabetes were associated with the onset of diabetes after surgery. T3cDM appeared as a heterogeneous entity strongly overlapped with type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference American Diabetes Association (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care 37(Suppl 1):S81–S90. doi:10.2337/dc14-S081 American Diabetes Association (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care 37(Suppl 1):S81–S90. doi:10.​2337/​dc14-S081
4.
go back to reference Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B (2010) Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 33(12):2677–2683. doi:10.2337/dc10-1279 PubMedCrossRefPubMedCentral Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B (2010) Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 33(12):2677–2683. doi:10.​2337/​dc10-1279 PubMedCrossRefPubMedCentral
6.
go back to reference Lemmens VE, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JW, de Hingh IH (2011) Improving outcome for patients with pancreatic cancer through centralization. Br J Surg 98(10):1455–1462. doi:10.1002/bjs.7581 PubMedCrossRef Lemmens VE, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JW, de Hingh IH (2011) Improving outcome for patients with pancreatic cancer through centralization. Br J Surg 98(10):1455–1462. doi:10.​1002/​bjs.​7581 PubMedCrossRef
7.
go back to reference Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, Cardillo M, Melzi R, Mercalli A, Sordi V, Lampasona V, Espadas de Arias A, Scalamogna M, Bosi E, Bonifacio E, Secchi A, Terasaki PI (2013) Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes 62(5):1656–1664. doi:10.2337/db12-1258 PubMedCrossRefPubMedCentral Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, Cardillo M, Melzi R, Mercalli A, Sordi V, Lampasona V, Espadas de Arias A, Scalamogna M, Bosi E, Bonifacio E, Secchi A, Terasaki PI (2013) Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes 62(5):1656–1664. doi:10.​2337/​db12-1258 PubMedCrossRefPubMedCentral
9.
12.
go back to reference Damiano J, Bordier L, Le Berre JP, Margery J, Dupuy O, Mayaudon H, Bauduceau B (2004) Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab 30(2):203–207. doi:DM-04-2004-30-2-1262-3636-101019-ART16 Damiano J, Bordier L, Le Berre JP, Margery J, Dupuy O, Mayaudon H, Bauduceau B (2004) Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab 30(2):203–207. doi:DM-04-2004-30-2-1262-3636-101019-ART16
13.
go back to reference Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST (2007) Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 102(10):2157–2163. doi:10.1111/j.1572-0241.2007.01480.x PubMedCrossRef Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST (2007) Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 102(10):2157–2163. doi:10.​1111/​j.​1572-0241.​2007.​01480.​x PubMedCrossRef
14.
go back to reference Garancini MP, Calori G, Ruotolo G, Manara E, Izzo A, Ebbli E, Bozzetti AM, Boari L, Lazzari P, Gallus G (1995) Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia 38(3):306–313. doi:10.1007/BF00400635 PubMedCrossRef Garancini MP, Calori G, Ruotolo G, Manara E, Izzo A, Ebbli E, Bozzetti AM, Boari L, Lazzari P, Gallus G (1995) Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia 38(3):306–313. doi:10.​1007/​BF00400635 PubMedCrossRef
15.
go back to reference Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57(6):1638–1644. doi:10.2337/db07-0954 PubMedCrossRef Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57(6):1638–1644. doi:10.​2337/​db07-0954 PubMedCrossRef
17.
go back to reference Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F, Bosi E (2007) High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30(4):932–938. doi:10.2337/dc06-1696 PubMedCrossRef Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F, Bosi E (2007) High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30(4):932–938. doi:10.​2337/​dc06-1696 PubMedCrossRef
25.
26.
go back to reference Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, Giunco S, Valerio A, Navaglia F, Zambon CF, Falda A, Pedrazzoli S, Plebani M (2006) Pancreatic cancer-derived S-100A8N-terminal peptide: a diabetes cause? Clin Chim Acta 372(1–2):120–128. doi:10.1016/j.cca.2006.03.027 PubMedCrossRef Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, Giunco S, Valerio A, Navaglia F, Zambon CF, Falda A, Pedrazzoli S, Plebani M (2006) Pancreatic cancer-derived S-100A8N-terminal peptide: a diabetes cause? Clin Chim Acta 372(1–2):120–128. doi:10.​1016/​j.​cca.​2006.​03.​027 PubMedCrossRef
27.
go back to reference Aggarwal G, Ramachandran V, Javeed N, Arumugam T, Dutta S, Klee GG, Klee EW, Smyrk TC, Bamlet W, Han JJ, Rumie Vittar NB, de Andrade M, Mukhopadhyay D, Petersen GM, Fernandez-Zapico ME, Logsdon CD, Chari ST (2012) Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology 143(6):1510–1517 e1511. doi:10.1053/j.gastro.2012.08.044 Aggarwal G, Ramachandran V, Javeed N, Arumugam T, Dutta S, Klee GG, Klee EW, Smyrk TC, Bamlet W, Han JJ, Rumie Vittar NB, de Andrade M, Mukhopadhyay D, Petersen GM, Fernandez-Zapico ME, Logsdon CD, Chari ST (2012) Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology 143(6):1510–1517 e1511. doi:10.​1053/​j.​gastro.​2012.​08.​044
29.
go back to reference Pannala R, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM, Chari ST (2009) Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 104(9):2318–2325. doi:10.1038/ajg.2009.253 PubMedCrossRefPubMedCentral Pannala R, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM, Chari ST (2009) Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 104(9):2318–2325. doi:10.​1038/​ajg.​2009.​253 PubMedCrossRefPubMedCentral
31.
go back to reference Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J (1993) Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 80(8):1047–1050PubMedCrossRef Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J (1993) Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 80(8):1047–1050PubMedCrossRef
32.
go back to reference Fogar P, Pasquali C, Basso D, Sperti C, Panozzo MP, Tessari G, D’Angeli F, Del Favero G, Plebani M (1994) Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res 14(6B):2827–2830PubMed Fogar P, Pasquali C, Basso D, Sperti C, Panozzo MP, Tessari G, D’Angeli F, Del Favero G, Plebani M (1994) Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res 14(6B):2827–2830PubMed
36.
go back to reference Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol 49(6):421–428. doi:10.1007/s00592-011-0361-2 PubMedCrossRef Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol 49(6):421–428. doi:10.​1007/​s00592-011-0361-2 PubMedCrossRef
Metadata
Title
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients
Authors
Gianpaolo Balzano
Erica Dugnani
Valentina Pasquale
Giovanni Capretti
Maria Grazia Radaelli
Tania Garito
Gregorio Stratta
Alessandro Nini
Raffaele Di Fenza
Renato Castoldi
Carlo Staudacher
Michele Reni
Marina Scavini
Claudio Doglioni
Lorenzo Piemonti
Publication date
01-10-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0614-y

Other articles of this Issue 5/2014

Acta Diabetologica 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.